Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Research & Development (2016 - 2022)

Collegium Pharmaceutical has reported Research & Development over the past 7 years, most recently at $4.0 million for Q1 2022.

  • Quarterly results put Research & Development at $4.0 million for Q1 2022, up 35.94% from a year ago — trailing twelve months through Dec 2022 was $4.0 million (down 57.86% YoY), and the annual figure for FY2022 was $4.0 million, down 57.86%.
  • Research & Development for Q1 2022 was $4.0 million at Collegium Pharmaceutical, up from $1.6 million in the prior quarter.
  • Over the last five years, Research & Development for COLL hit a ceiling of $4.0 million in Q1 2022 and a floor of $1.4 million in Q3 2021.
  • Median Research & Development over the past 5 years was $2.5 million (2019), compared with a mean of $2.5 million.
  • Peak annual rise in Research & Development hit 38.87% in 2021, while the deepest fall reached 34.91% in 2021.
  • Collegium Pharmaceutical's Research & Development stood at $2.2 million in 2018, then increased by 6.63% to $2.4 million in 2019, then grew by 3.09% to $2.5 million in 2020, then plummeted by 34.91% to $1.6 million in 2021, then surged by 147.55% to $4.0 million in 2022.
  • The last three reported values for Research & Development were $4.0 million (Q1 2022), $1.6 million (Q4 2021), and $1.4 million (Q3 2021) per Business Quant data.